Scientific Programme

Thursday 11 April 2019

09.00   Registration Opens

11.00 – 11.10   Welcome Address
Christoph Zielinski, Vienna, Austria

11.10 – 11.30   Opening Lecture: Immunotherapy – next challenges of clinical drug development
Mario Sznol, New Haven, CT, USA

11.30 – 13.00   Plenary Symposium 1 – Microenvironment and metabolism

  • Imaging of T cell success and failure within the tumor microenvironment
    Emmanuel Donnadieu, Paris, France
  • Role of TGFß and CAFs in T cell exclusion”
    Eduard Batlle, Barcelona, Spain
  • Checkpoint inhibition and metabolic reprogramming
    Bo Huang, Beijing, China
  • Role of intratumoral memory T cells for immune surveillance
    Pedro Romero, Lausanne, Switzerland
  • Hypoxia and microenvironment
    NN

13.30 – 14.30   Lunch

14.30 – 16.00   Plenary Symposium 2 – Emerging Concepts / New Agents

  • Microbiota and its role for response to immunotherapy
    TBC
  • Targeting the CF73-adenosine axis for immunotherapy
    Paolo Ascierto, Naples Italy
  • Modulation of checkpoint antibodies
    TBC
  • Bispecific immune modulators
    TBC
  • NK cells as target for therapeutic intervention
    Eric Vivier, Marseille, France

16.00 – 16.30   Coffee Break

16.30 – 18.30   Plenary Symposium 3 – Combination Therapy

  • Rationales for combination strategies
    Samir Khleif, Augusta, GA, USA
  • Combination of checkpoint inhibition and vaccines
    Sjoerd van der Burg, Leiden, The Netherlands
  •  Interaction between cytokines and checkpoint inhibitors
    Aaron Ring, New Haven, CT, USA
  • Combination of Oncolytic Viruses and Checkpoint Inhibitors
    Alan Melcher, London, United Kingdom

18.30   Welcome Reception and Poster Viewing

 

Friday 12 April 2019

08.30 – 09.30   TNBC (Triple Negative Breast Cancer) Meet the Expert Session

09.30 – 10.30   Plenary Symposium 4 – Preclinical Models

  • Tumor organoids and immune cells
    Emile Voest,  Amsterdam, The Netherlands
  • In vivo imaging of immune responses using PET-CT
    Angela Krackhardt, Munich, Germany
  • Prediction of efficacy and toxicity of immunotherapeutic agents
    NN

10.30 – 11.00   Coffee Break

11.00 – 13.00   Plenary Symposium 5 – Precision Medicine Meets Immunotherapy

  • Challenges of including immunobiomarkers into clinical drug development
    Jeffrey Weber, New York, NY, USA
  • Circulating tumor DNA as a tool to predict response in immunotherapy
    François-Clément Bidard, Paris, France
  • T Cell subpopulations predict response to immunotherapy
    NN

13.00 – 14.00   Lunch

 14.00 – 14.30   Poster Viewing with Presenters

14.30 – 15.15   Lifetime Achievement Award

  • Innate Immunity, Inflammation and Cancer: from bench to bedside
    Alberto Mantovani, Milan, Italy

15.15 – 15.45   Coffee Break

15.45 – 17.20   Plenary Symposium 6 – Cell Therapy

  • Next generation cell therapies
    Lisa Butterfield, San Francisco, CA, United States
  • TRUCKs
    Hinrich Abken, Regensburg, Germany
  • Synthetic agonist receptor modified T cells: a new modular platform for T-cell therapy
    Sebastian Kobold, Munich, Germany
  • CAR-NK cell therapy
    Ulrike Koehl, Leipzig, Germany

17.20 – 18.20   Plenary Session 7: Young Researcher Session

19.15 – 19.45   Exhibitors (Pipeline) Session

  • NANOSTRING
  • FLUIDIGM
    “Define the Tumor Microenvironment with CyTOF technology and microfluidics solutions”
    Fludigm enables the comprehensive cellular and molecular profiling of the immune system and the tumor microenvironment with proven mass cytometry, Imaging Mass Cytometry™ (IMC™) and automated microfluidics solutions. Whether you seek to target new biomarkers and pathways or to optimize the effectiveness of checkpoint inhibitors, CAR T cells or cancer vaccines, Fluidigm can help you identify new insights to reach your next research breakthrough.

20.00   ITOC6 Conference Dinner

 

Saturday 13 April 2019

08.30 – 10.00   Meet the Expert Session

10.00 – 10.30    Coffee Break

10.30 – 12.10  Plenary Symposium 8 – Clinical Breakthrough with Immunotherapy
Joint Session with ESMO

  • Immune related adverse events
    Michael von Bergwelt, Munich, Germany
  • Cell Therapy
    John Haanen, Amsterdam, The Netherlands
  • NSCLC
    NN
  • Melanoma
    NN

12.10 – 12.30   Best Poster Awards & Closing Remarks

12.30 – 13.30   Lunch